Exelixis (EXEL) to Release Earnings on Tuesday

Exelixis (NASDAQ:EXEL) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $497.89 million for the quarter.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts expect Exelixis to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Exelixis Stock Down 1.7 %

EXEL opened at $35.59 on Tuesday. The company has a market capitalization of $9.96 billion, a price-to-earnings ratio of 20.11, a PEG ratio of 1.13 and a beta of 0.57. The firm has a 50-day moving average price of $36.49 and a 200-day moving average price of $34.42. Exelixis has a twelve month low of $20.14 and a twelve month high of $40.02.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of analyst reports. Royal Bank of Canada boosted their target price on shares of Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, March 13th. Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Exelixis in a report on Thursday, March 27th. UBS Group reaffirmed an “underperform” rating on shares of Exelixis in a research note on Thursday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.59.

Insider Activity

In related news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. The trade was a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 140,343 shares of company stock valued at $5,177,234. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.